FLGS-03. Fluorescein sodium-guided biopsy or resection in patients with contrast enhancing brainstem lesion in MRI

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi226-vi226
Author(s):  
Fuhua Lin ◽  
Zhenghe Chen ◽  
Xiangheng Zhang ◽  
Yonggao Mou
Keyword(s):  
Small Cell Lung Carcinoma ◽  
Cancer Center ◽  
Sodium Fluorescein ◽  
Target Area ◽  
Fluorescein Sodium ◽  
Fluorescence Staining ◽  
Strong Fluorescence ◽  
Cell Lung Carcinoma ◽  
Brainstem Lesion ◽  
Guided Surgery

Abstract BACKGROUND It is challenging to resect or just biopsy the lesions in the brainstem, due to the essential function of the surfaces and limited space. Neuro-navigation is not always reliable and stereotatic biopsy is infrequently inconclusive due to small or inadequate samples. We want to share our experiences in the application of fluorescein sodium in surgery on patients with brainstem lesion which is contrast enhancing in MRI. METHODS Between January 2017 and June 2021, 5 patients with brainstem lesion underwent fluorescein sodium-guided surgery in neurosurgery department of Sun Yat-sen University Cancer Center. After injection of low dose of sodium fluorescein (3 mg/kg), the lesions with strong fluorescence staining were identified as the target area for biopsy or resection. RESULTS 5 consecutive patients (aged 6–47 years) with brainstem lesions prospectively underwent fluorescein sodium-guided surgery. The lesions were located in pontine in 3 patients and in the medulla in 2 patients. Gross total resection was achieved in 2 patients, and partial resection in the other 3 patients. In all patients, a pathological diagnosis was obtained (4 gliomas and 1 metastasis from non-small cell lung carcinoma) without severe complications, including mild facial or abduct nerve palsy in 3 patients. And all the specimens with strong fluorescence staining sent for pathology were proved to be tumorous. CONCLUSION Fluorescein sodium-guided technique was helpful to locate the lesion in brainstem which was contrast-enhanced in MRI. It was effective and safe to figure out an ideal trajectory to avoid damage of the crucial structures and improve the diagnostic rate.

Der Einfluss des Alters auf die Morbidität und Mortalität bei operablen Lungenkrebspatienten im Stadium I

2019 ◽  
Vol 7 (3) ◽  
pp. 142-143
Author(s):  
Khosro Hekmat
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Cancer Center ◽  
Small Cell Lung ◽  
Multivariate Analyse ◽  
Cell Lung Carcinoma ◽  
Postoperative Morbidität ◽  
Stadium I

Die vorliegende Studie befasst sich mit dem Einfluss des Alters auf die postoperative Morbidität und Mortalität nach Lungenresektion bei Patienten mit einem nicht kleinzelligen Bronchialkarzinom (non-small cell lung carcinoma, NSCLC) im Stadium I. Am Sloan Kettering Cancer Center (USA) wurden in den Jahren 2000-2011 insgesamt 5371 Patienten einer Lungenresektion unterzogen. 2186 Patienten befanden sich im Stadium I eines NSCLC und wurden in die Studie eingeschlossen. Die multivariate Analyse zeigte, dass die Lungendiffusion (DLCO) ein unabhängiger Prädiktor für die Morbidität, Einjahresmortalität und nicht krebsspezifische Mortalität war. Im Gegensatz dazu war die Einsekundenkapazität (FEV1) ein signifikanter Risikofaktor für die krebsspezifische Mortalität. Die vorliegende Studie zeigt die Relevanz der präoperativen Lungenfunktion mit Bestimmung der DLCO und FEV1. Bei älteren Patienten mit Lungenresektion im Stadium I eines NSCLC ist die nicht krebsspezifische Sterblichkeit in der Frühphase nach der Operation bedeutsam.

Can hippocampus be spared in patients with small cell lung carcinoma (SCLC) during cranial radiation therapy (CRT)?

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7596-7596
Author(s):  
Vijayananda Kundapur ◽  
Tasha Ellchuk ◽  
Shahid Ahmed
Keyword(s):  
De Novo ◽  
Radiation Treatment ◽  
Small Cell Lung Carcinoma ◽  
Final Analysis ◽  
Cranial Irradiation ◽  
Prophylactic Cranial Irradiation ◽  
Cancer Center ◽  
Binary Logistic Regression Analysis ◽  
Clinical Factors ◽  
Cell Lung Carcinoma

7596 Background: Although CRT is a standard therapy for prevention and treatment of brain metastases (BM) in patients with SCLC, neurocognitive impairment (NI) following therapeutic whole brain radiation treatment (WBRT) or prophylactic cranial irradiation (PCI) is a major problem and can cause impairment in quality of life. A RTOG study is assessing various outcomes by avoiding the hippocampus (AH) during WBRT in different malignancies. The estimated risk of hippocampal avoidance region metastases (HM) in patients with SCLC before & after WBRT/PCI is not known. AH during CRT may delay the onset of NI in such patients. Our study aims to determine risk of HM in patients with SCLC and to assess clinical factors correlate with it. Methods: A patients cohort of SCLC diagnosed and treated at the Saskatoon Cancer Center between 2005 and 2012 were followed. All MRI and/or CT scans were independently reviewed by a neuroradiologist. HM was defined as BM within 5 mm of hippocampus. Binary Logistic regression analysis was done to assess correlation between various clinical variables and HM using SPSS. Results: 162 patients with SCLC were identified, 60 (37%) have developed BM. The preliminary data of 39/60 patients is presented here. All 39 patients received CRT and 17 patients received upfront chemotherapy. Their median age was 63 yrs (range: 41-82) & M:F was 22:17. 30 (77%) had extensive stage SCLC and 30 (77%) had de novo BM before CRT. A total 198 (range: 1-33) BM were identified among these patients with a mean BM of 6.6 per patient. 4 (13.3%) of 30 patients had HM involvement with mean BM of 1.3 per patient. Median follow up was 13.5 months (range: 1-69). Post-CRT 13 (33%) of 39 patients (4 PCI, 9 WBRT) developed central nervous system (CNS) progression. None of 13 patients with CNS failure following CRT developed HM. Overall 4 (10.2%) of 39 patients developed HM. No clinical factors significantly correlated with HM. Conclusions: The preliminary result revealed that overall incidence of HM before and after WBRT/PCI is low. AH in such patients may consider during CRT to avoid NI. The study is ongoing and final analysis will be presented.

Effects of MicroRNA-22 (miR-222) on Non-Small-Cell Lung Carcinoma (NSCLC) Cells Apoptosis and Proliferation Through Protein Kinase B/Mammalian Target of Rapamycin (AKT/mTOR) Signaling Pathway

2021 ◽  
Vol 11 (7) ◽  
pp. 1346-1351
Author(s):  
Xiaowei Xie ◽  
Jiansheng Lin ◽  
Mingqiang Kang ◽  
Ying Guo
Keyword(s):  
Cell Apoptosis ◽  
Small Cell Lung Carcinoma ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway ◽  
Hoechst 33258 ◽  
Small Cell Lung ◽  
Fluorescence Staining ◽  
Cell Lung Carcinoma ◽  
Mtor Protein

Our study investigated miR-222’s effect on NSCLC apoptosis and proliferation. H1650 cells were assigned into NSCLC group, SI group and IN group followed by analysis of Akt-mTOR protein content, cell apoptosis and proliferation, and miR-222 expression by Western blot, Hoechst 33258 fluorescence staining, qRT-PCR, cck-8, and immunohistochemistry miR-222 expression was lowest in IN group and highest in SI group (P < 0.05). The nucleus shrinkage rate in IN group and NSCLC group was significantly higher than that in SI group (P < 0.05) with NSCLC group showed more cells apoptosis than IN group (P < 0.05). The SI group had significantly higher OD value than IN group and NSCLC group (P < 0.05) with NSCLC group having significantly higher OD value than IN group (P < 0.05). The Akt-mTOR and p-Akt/p-mTOR expression was lowest in IN group and highest in SI group (P < 0.05) with lower level in IN group than NSCLC group (P < 0.05). The number of positive Akt-mTOR of H1650 cells was highest in SI group while lowest in IN group (P < 0.05). The decreased miR-222 expression in NSCLC can promote cancer cell apoptosis and inhibit lung cancer development, which may be via down-regulating Akt-mTOR signaling.

PET response following stereotactic body radiotherapy for non-small cell lung carcinoma correlates with local control

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18013-18013
Author(s):  
S. J. Feigenberg ◽  
J. Q. Yu ◽  
T. Eade ◽  
M. Buyyounouski ◽  
L. Wang ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Stereotactic Body Radiotherapy ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Pet Scan ◽  
Cancer Center ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Imaging Results ◽  
Prospective Study Design

18013 Background: Given the success of Stereotactic Body Radiotherapy (SBRT) for Non-Small Cell Lung Carcinoma (NSCLC), early surrogates of local failure (LF) are necessary to allow timely surgical salvage. This study tries to determine the utility of PET response as an early surrogate for LF. Methods: Eligible patients(pts) had biopsy proven NSCLC < 5 cm in size who underwent a pre- and post- SBRT PET scans. Pts treated at Fox Chase Cancer Center were either: 1. early stage (10 pts), 2. biopsy-proven local recurrences (4 patients) or 3. oligometastases (3 patients). Eleven of the 17 pts were treated on a prospective phase I dose escalation protocol and received either 40 Gy or 48 Gy in 4 fractions over 8 days. Non-protocol pts generally received 48 Gy in 4 fractions (5 of 6 pts). Treatment volumes were individualized for each pt using either 4 D or multi-phase CT simulation. As part of the prospective study design, PETs scan was obtained pre- and post-SBRT to correlate metabolic response with LF based on the work by MacManus. The post-SBRT PET scan was obtained at a median of 3 months following treatment (range, 2 to 6 months). LF was defined by my an increase in size on CT on serial imaging. Results: With a median follow up of 14 months (range 4 to 31 months), 3 LF have been documented. The median SUV max pre-SBRT was 4.7 (range 1.32 to 18.2) and 1.9 (range 0.9 to 7.0) post-SBRT. Only four pts had a post-SBRT SUV max > 2.5 (2.8, 5.1, 5.3 and 7). Overall, twelve pts had a drop in their SUV max following SBRT, while 1 pt had stabilization and 4 had an increase . Of these last 5 pts, 3 developed LF. The other two have been followed without any intervention and remain free of recurrence for > 2 years, respectively. No pt with an initial drop in post SBRT PET scan SUV has had LF. Conclusions: PET response (defined as a drop in the SUV max by 3 months) correlates with LF, and appears to be a good early surrogate of outcomes following SBRT. Larger studies are required to confirm this finding. No significant financial relationships to disclose.

Platinum based chemotherapy in elderly patients with non-small cell lung carcinoma (NSCLC): Experience from an Indian tertiary cancer center.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20528-e20528
Author(s):  
Aparna Sharma ◽  
Sachin Khurana ◽  
Raja Pramanik ◽  
Sunil Kumar ◽  
Sushmita Pathy ◽  
...  
Keyword(s):  
Adverse Events ◽  
Small Cell Lung Carcinoma ◽  
Eastern Cooperative Oncology Group ◽  
Weekly Paclitaxel ◽  
Cancer Center ◽  
Hematological Toxicity ◽  
Study Cohort ◽  
Cell Lung Carcinoma ◽  
Platinum Based Chemotherapy ◽  
Study Population

e20528 Background: Instituting platinum based chemotherapy in elderly population is often associated with poor tolerance and attending toxicities. We present our limited center experience of chemotherapy in the geriatric population group. Methods: This is a retrospective single center experience of all registered patients in lung cancer clinic (LCC) in the department of medical oncology, Dr. B.R.A. IRCH, AIIMS. All histopathologically proven cases of NSCLC with age more than 70 years who received platinum based chemotherapy (single/doublet) with complete patient records were analysed. The study was carried out between November 2016 and August 2018.Data was analysed using STATA v13. Results: The cohort consisted of 25 patients who satisfied the inclusion criteria. Males comprised 84%(n = 21) of the cohort. Median age of study population was 72.7 years years (Range 70-84). 36%(n = 9) of the study population had one comorbidity while 8% (n = 2) had multiple comorbidities. 68% (n = 17) of the cohort were smokers. ECOG(Eastern cooperative oncology group) PS (performance status) 1 was seen in 48% (n = 12) and PS 2 in 32% (n = 8) and PS 3 in 16% (n = 4) respectively of the patients. Histopathologically, 48% (n = 12) of the population constituted squamous cell carcinoma while 40%(n = 10) had adenocarcinoma. 76%(n = 19) patients had Stage 4 NSCLC. Most common chemotherapy regimes used were weekly Paclitaxel carboplatin (n = 11, 44%), three weekly paclitaxel carboplatin (n = 8 , 32%) Pemetrexed carboplatin (n = 5, 20%) and gemcitabine carboplatin (n = 1, 4%). Only 12% (n = 3) could complete more than 4 cycles of chemotherapy and 3 could receive maintenance chemotherapy. Best responses according to RECIST (Response Evaluation Criteria In Solid Tumors) criteria v1.1 achieved were complete response in 12%(n = 3), partial response in 16% (n = 4), stable disease 24%(n = 6) and progressive disease in 48%(n = 12). Most common grade 3 and 4 adverse events according to CTCAE (common terminology criteria for adverse events) v4.03 were mucositis 29.17%(n = 7), diarrhea 12% (n = 3), peripheral neuropathy 12.5 (n = 3) and hematological toxicity 16%(n = 4). Conclusions: The patient number in this study cohort is limited.However, our experience demonstrates that abbreviated therapy in elderly subgroup is fairly well tolerated. Various tools like comprehensive geriatric assessment need to be utilized to provided tailored therapy in the elderly subgroup. A prospective study is required to address the efficacy and toxicity profile of chemotherapy in this select population.

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

Evaluation of Potent Isoquinoline-Based Thiosemicarbazone Antiproliferatives Against Solid Tumor Models

2019 ◽  
Author(s):  
Daniel Sun ◽  
Soumya Poddar ◽  
Roy D. Pan ◽  
Juno Van Valkenburgh ◽  
Ethan Rosser ◽  
...  
Keyword(s):  
Solid Tumor ◽  
Small Cell Lung Carcinoma ◽  
Single Agent ◽  
Resistance Mechanisms ◽  
Tumor Models ◽  
Cell Lung Carcinoma ◽  
Adaptive Resistance ◽  
Cancer Models ◽  
Nanomolar Range

The lead compound, an ⍺-N-heterocyclic carboxaldehyde thiosemicarbazone <b>HCT-13</b>, was highly potent against a panel of pancreatic, small cell lung carcinoma, and prostate cancer models, with IC<sub>90</sub> values in the low-to-mid nanomolar range.<b> </b>We show that the cytotoxicity of <b>HCT-13</b> is copper-dependent, that it acts as a copper ionophore, induces production of reactive oxygen species (ROS), and promotes mitochondrial dysfunction and S-phase arrest. Lastly, DNA damage response/replication stress response (DDR/RSR) pathways, specifically Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (ATR), were identified as actionable adaptive resistance mechanisms following <b>HCT-13 </b>treatment. Taken together, <b>HCT-13 </b>is potent against solid tumor models and warrants <i>in vivo</i> evaluation against aggressive tumor models, either as a single agent or as part of a combination therapy.

Sign in / Sign up

Export Citation Format

Share Document